Topical hemostatic products containing
thrombin are commonly used in
burn surgery to facilitate focal hemostasis and
graft adherence. Until recently,
thrombin was available only from a bovine source, which has been documented to produce
antibodies to endogenous clotting factors and to induce coagulation defects and severe
bleeding complications. This report documents the first case of
factor V deficiency and profound coagulopathy in a
burn patient after intraoperative exposure to bovine
thrombin. A 38-year-old woman was admitted after a 75% total body surface area
burn. The patient underwent repeated excision and grafting during which an
epinephrine solution that contained bovine
thrombin was used to facilitate hemostasis. During the fourth and subsequent operative procedures, the patient developed profound coagulopathy as evidenced by excessive
bleeding and abnormal laboratory coagulation parameters, requiring the administration of supplemental clotting factors through fresh frozen plasma and cryoprecipitate. Hematology work-up revealed
a factor V deficiency. Subsequent procedures in which bovine
thrombin was avoided were uneventful. The use of topical bovine
thrombin in patients who have been previously exposed results in an increased risk of perioperative coagulopathy and clinically significant
bleeding complications. Thus, the use of bovine-
thrombin-containing products should be avoided in
burn patients with prior exposure to bovine
thrombin.